Cellectis (CLLS) Non Operating Income (2015 - 2026)
Cellectis (CLLS) recorded quarterly Non Operating Income of $7.4 million in Q1 2026, down 56.48% quarter-over-quarter from $17.1 million in Q4 2025, and up 288.68% on a YoY basis from $1.9 million in Q1 2025.
Cellectis (CLLS) Non Operating Income (2015 - 2026) Analysis & Trends
Cellectis' Non Operating Income history runs 12 years deep, the most recent figure standing at $7.4 million for Q1 2026.
- In Q1 2026, Non Operating Income rose 288.68% year-over-year to $7.4 million; the TTM figure through Mar 2026 stood at $3.0 million (up 139.88% YoY), while the FY2025 annual figure was -$34.9 million, down 253.29% from the prior year.
- Non Operating Income was $7.4 million for Q1 2026 at Cellectis, down from $17.1 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $26.3 million in Q1 2024 to a low of -$20.0 million in Q4 2022.
- Historically, Non Operating Income has averaged -$369882.4 across 5 years, with a median of -$3.9 million in 2025.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income sank 737.74% in 2022, then jumped 696.89% in 2024.
- A 5-year view of Non Operating Income shows it stood at -$20.0 million in 2022, then soared by 38.81% to -$12.2 million in 2023, then surged by 240.17% to $17.1 million in 2024, then changed by 0.0% to $17.1 million in 2025, then slumped by 56.48% to $7.4 million in 2026.
- The last three Non Operating Income figures came in at $7.4 million (Q1 2026), $17.1 million (Q4 2025), and -$7.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | 7.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.45 Mn |
| Dec 31, 2025 | 17.12 Mn |
| Sep 30, 2025 | -7.45 Mn |
| Jun 30, 2025 | -14.15 Mn |
| Mar 31, 2025 | -3.95 Mn |
| Dec 31, 2024 | 17.12 Mn |
| Sep 30, 2024 | -12.35 Mn |
| Jun 30, 2024 | -8.25 Mn |
| Mar 31, 2024 | 26.28 Mn |
| Dec 31, 2023 | -12.21 Mn |
| Sep 30, 2023 | 3.30 Mn |
| Jun 30, 2023 | -5.84 Mn |
| Mar 31, 2023 | -4.40 Mn |
| Dec 31, 2022 | -19.96 Mn |
| Sep 30, 2022 | 1.81 Mn |
| Jun 30, 2022 | 8.30 Mn |
| Mar 31, 2022 | 912,000.00 |
| Dec 31, 2021 | 3.13 Mn |
| Sep 30, 2021 | 2.30 Mn |
| Jun 30, 2021 | -4.13 Mn |